November 23, 2026:


The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) for children aged 2.5 years and older with growth failure from Turner syndrome, Novo announced Friday, Nov. 20. In the single trial behind the approval, 68 girls on weekly Sogroya grew 8.9 cm (3.5 in) a year, against 9.7 cm (3.8 in) for 37 girls on daily somatropin, an average gap of 0.8 cm (0.3 in) a year at week 52. Families choosing between 52 injections a year and 365 are trading fewer shots against that gap.
Novo’s press release printed two different 95% confidence intervals for the gap, one that includes zero and one that does not. The FDA-approved label carries the interval that includes zero, and it states no non-inferiority margin, the pre-set limit that decides whether growth counts as comparable. Without that margin, neither interval can show whether growth was comparable.
The press release’s text and table disagree. The text gave the difference as -1.58 to 0.07 cm (-0.62 to 0.03 in) a year, while its table gave -1.57 to -0.11 cm (-0.62 to -0.04 in). The label’s Section 14.5 lists -1.58 to 0.07, matching the text. The reason the table’s numbers differ is unknown.
A non-inferiority trial asks whether a new treatment is worse than an existing one by no more than a pre-set margin, so it specifies only a lower bound. The decision compares the interval’s lower end with that margin. Whether the interval includes zero does not settle it: an interval that excludes zero can still be non-inferior if the margin is wide, and one that includes zero can still fail if the margin is tight. Contemporary Pediatrics, which covered the approval, did not report a margin either.
What the label’s estimated treatment difference says: at 52 weeks, the data are consistent with weekly dosing growing girls anywhere from 1.58 cm (0.62 in) a year less to 0.07 cm (0.03 in) more than daily dosing.
The primary endpoint was annualized height velocity at week 52 in a randomized, open-label trial of 105 girls aged 2.5 to 10, none previously treated with growth hormone. Open-label means families and doctors knew which injection they were using.
| Week 52 result | Weekly Sogroya (68 girls) | Daily somatropin (37 girls) |
|---|---|---|
| Annualized height velocity | 8.9 cm (3.5 in) a year | 9.7 cm (3.8 in) a year |
| Baseline height SDS | -2.8 | -3.0 |
| Change in height SDS | +0.77 | +0.86 |
These figures come from Section 14.5 of the label. Height SDS is a standard-deviation score comparing a child’s height with the average for her age. Both measures moved the same direction: weekly dosing trailed numerically.
Novo’s other three REAL8 baskets did not show a gap that size. Weekly Sogroya grew children with Noonan syndrome 10.4 cm (4.1 in) a year against 9.2 cm (3.6 in) on daily dosing, a lead of 1.2 cm (0.5 in). In children born small for gestational age it grew 11.0 cm (4.3 in) a year against 11.1 cm (4.4 in) on a higher daily dose, and 9.4 cm (3.7 in) on a lower one. In idiopathic short stature it trailed, 10.2 versus 10.5 cm (4.0 versus 4.1 in). Turner syndrome’s 0.8 cm (0.3 in) shortfall is the widest of the numerical deficits. The baskets used different comparators and sample sizes, so they are not head-to-head.
The 2024 international guidelines say Turner syndrome affects 50 per 100,000 females. They recommend offering growth hormone early because growth failure begins before birth and is rapid in the first years of life, and say treatment should continue until little growth potential remains, meaning a bone age of 14 or more and/or height velocity under 2 cm (0.8 in) a year. Without treatment, adult women with Turner syndrome average about 20 cm (7.9 in) shorter than other women. Growth hormone adds roughly 7 cm (2.8 in) to expected adult height. Turner syndrome also brings heart and kidney differences, as well as infertility from ovarian insufficiency.
The daily arm received 0.05 mg/kg a day (0.023 mg/lb a day), or 0.35 mg/kg a week (0.16 mg/lb a week). The guidelines’ recommended starting dose is 45 to 50 micrograms per kilogram a day (20 to 23 micrograms per pound), rising to a maximum of 68 (31 per pound). Novo’s release says the daily dose sat below the U.S. maximum of 0.067 mg/kg a day (0.030 mg/lb a day) for pediatric Turner syndrome. Contemporary Pediatrics also noted the daily dose was below the labeled maximum, so the trial leaves open how weekly dosing compares with higher daily doses.
The weekly arm received 0.24 mg/kg a week (0.11 mg/lb). That is a smaller mass than the daily arm’s weekly total, but the molecules differ, so the mass doses are not directly comparable. The label says dosing should be individualized to growth response, and the trial tested one dose level per arm, so it does not show whether adjusting doses changes the gap.
Sogroya’s active ingredient, somapacitan, is human growth hormone with one amino acid swapped (leucine 101 for cysteine) and a side chain built from a fatty acid and hydrophilic spacer attached there. That side chain, about 1.2 kilodaltons in size, binds reversibly to albumin in blood, which slows elimination and extends the drug’s half-life enough for weekly dosing. Insulin detemir, liraglutide and once-weekly semaglutide use the same protraction approach.
That design conflicts with how Novo’s release describes the drug. One section calls Sogroya the same growth hormone the body makes, and another calls it a human growth hormone analog. The side chain makes analog the accurate term, and reference works call somapacitan an analog.
The binding also shapes handling. The label lets families take a missed dose within 3 days of the scheduled day and skip it after that. Rival weekly products use different chemistry. Ascendis’s Skytrofa is somatropin transiently conjugated to a carrier, so growth data from one product cannot be assumed to apply to another.
On March 17, Ascendis Pharma reported week 52 results from New InsiGHTS, a Phase 2, open-label U.S. trial of weekly TransCon hGH (lonapegsomatropin) in 49 children aged 1 to 10 with Turner syndrome. Growth averaged 9.05 cm (3.6 in) a year on weekly dosing and 9.04 cm (3.6 in) on daily somatropin. Doses were individualized to IGF-1 and averaged 0.22 mg/kg a week (0.10 mg/lb) for TransCon hGH and 0.29 mg/kg a week (0.13 mg/lb) for daily somatropin. Ascendis reported no confidence intervals, and its release says a recently initiated Phase 3 basket trial, HighLiGHts, will support label expansion without saying whether it includes Turner syndrome.
Cross-trial comparison is not valid: doses, ages, size and design differ. The result does show that matching average growth in Turner syndrome has been reported by a rival at one year, and that Novo’s headline claim of being the first and only weekly option for this use holds on the labels reviewed. Skytrofa’s label covers children 1 year and older weighing at least 11.5 kg (25.4 lb) and adults, with growth hormone deficiency only. FDA’s Ngenla page says the drug is indicated for children 3 and older with growth hormone deficiency and does not mention Turner syndrome.
Weekly dosing cuts a year of treatment from 365 injections to 52, and Dr. Aristides Maniatis, a REAL8 investigator, said in Novo’s release that this provides 313 injection-free days a year. The trial was not designed to test whether fewer injections improve adherence.
Independent evidence is thin. A 2025 conference abstract led by Bradley S. Miller of the University of Minnesota followed 19 children with growth hormone deficiency, four of whom switched to a weekly product, and found no significant change in adherence; the sample is tiny, and its lead author discloses relationships with Ascendis, Novo Nordisk and Pfizer. A 2026 review in Endocrine by Tornese and colleagues at the University of Trieste concluded that adherence in weekly-hormone trials may be overestimated, and called weekly dosing “a promising strategy to be rigorously tested, rather than a proven solution.” A 2025 study in Frontiers in Pediatrics reported higher adherence with long-acting products in a Chinese cohort, 94% against 91% for daily shots. None of this evidence isolates Turner syndrome.
The label’s Turner syndrome table of adverse reactions, covering reactions in at least 10% of girls, shows the following:
| Reaction | Daily somatropin (37 girls) | Weekly Sogroya (68 girls) |
|---|---|---|
| Respiratory tract infection | 35% | 32% |
| Nasopharyngitis | 24% | 32% |
| Ear infection | 19% | 22% |
| Fever | 14% | 21% |
| Diarrhea | 14% | 18% |
| Vomiting | 8% | 13% |
| Injection site reaction | 11% | 7% |
The groups are small and the trial was open-label, so the differences may be chance. Sogroya carries the usual growth hormone warnings: higher mortality in critically ill patients, tumor growth or recurrence, high blood sugar, increased skull pressure, serious allergic reactions, fluid retention, pancreatitis, worsening scoliosis and slipped capital femoral epiphysis. The label lists Turner syndrome among risk factors for diabetes and calls for periodic glucose monitoring. The release says not to use Sogroya in children with cancer or tumors, closed growth plates, or Prader-Willi syndrome with severe obesity or breathing problems.
The trial enrolled prepubertal girls aged 2.5 to 10 with a mean age of 6.2 who had never taken growth hormone. The label covers children 2.5 and older with no upper age, and its dosing section applies the same weekly dose to treatment-naive patients and to those switching from daily somatropin. For a switch, the label puts the last daily dose the day before, or at least 8 hours before, the first Sogroya dose. Because guidelines allow treatment to continue into adolescence, girls who could receive the drug include some older than anyone tested.
Height velocity at one year stands in for adult height, and adult height data are lacking. Growth hormone’s effect in Turner syndrome is strongest in the first year and tapers over time, so a one-year gap says little about what a repeating gap would mean by adulthood.
Novo’s release gives no U.S. price or launch date. The Turner Syndrome Foundation says growth hormone treatment can cost as much as $10,000 to $60,000 a year in the U.S. The FDA’s statistical review, the non-inferiority margin, the two-year safety extension of REAL8 and any adult-height data would settle what a one-year result cannot.
Weekly Sogroya trades 313 fewer injections a year for an average one-year growth gap of 0.8 cm (0.3 in) whose interval touches zero, a margin no one has published, a daily comparator dosed at the top of the guideline starting range, an untested adherence benefit and no adult-height data. Families can bring five questions to a pediatric endocrinologist: how the growth gap would be tracked at 6 and 12 months, what dose changes would follow slow growth, how a switch from daily shots would be monitored, what the cost and coverage will be, and when the plan would be revisited. Suspected side effects can be reported to the FDA through MedWatch.
At 52 weeks, girls on weekly Sogroya grew an average of 0.8 cm (0.3 in) a year less than girls on daily somatropin, with an interval of -1.58 to 0.07 cm (-0.62 to 0.03 in). Whether that counts as comparable depends on a margin that the label does not state, and no adult-height data exist yet.
No. A confidence interval including zero means the data cannot rule out no difference; it does not show the treatments are equivalent. In non-inferiority trials, only a lower bound is specified: the interval’s lower end is compared with a pre-set margin of acceptable difference, so an interval can include zero and still fall outside the margin.
The label gives dosing instructions for patients switching from daily somatropin. The Turner syndrome trial enrolled only treatment-naive girls, so it did not test a switch. A pediatric endocrinologist decides whether to switch and how to monitor growth afterward.
Novo’s release gives no U.S. price for the new indication. The Turner Syndrome Foundation puts growth hormone treatment at as much as $10,000 to $60,000 a year in the U.S.